757 related articles for article (PubMed ID: 18638459)
1. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.
Gyongyosi N; Balogh B; Kirilly E; Kitka T; Kantor S; Bagdy G
Brain Res; 2008 Sep; 1231():34-46. PubMed ID: 18638459
[TBL] [Abstract][Full Text] [Related]
2. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain.
Kirilly E
Neuropsychopharmacol Hung; 2010 Sep; 12(3):413-23. PubMed ID: 20962361
[TBL] [Abstract][Full Text] [Related]
3. Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.
Gyongyosi N; Balogh B; Katai Z; Molnar E; Laufer R; Tekes K; Bagdy G
J Neural Transm (Vienna); 2010 Mar; 117(3):285-92. PubMed ID: 20052506
[TBL] [Abstract][Full Text] [Related]
4. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC
J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558
[TBL] [Abstract][Full Text] [Related]
5. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
Camarasa J; Pubill D; Escubedo E
Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
[TBL] [Abstract][Full Text] [Related]
6. Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505.
Kantor S; Jakus R; Balogh B; Benko A; Bagdy G
Br J Pharmacol; 2004 Aug; 142(8):1332-42. PubMed ID: 15265808
[TBL] [Abstract][Full Text] [Related]
7. Serotonin control of sleep-wake behavior.
Monti JM
Sleep Med Rev; 2011 Aug; 15(4):269-81. PubMed ID: 21459634
[TBL] [Abstract][Full Text] [Related]
8. Activation of serotonin 5-HT(1B) receptor in the dorsal raphe nucleus affects REM sleep in the rat.
Monti JM; Jantos H; Lagos P
Behav Brain Res; 2010 Jan; 206(1):8-16. PubMed ID: 19737581
[TBL] [Abstract][Full Text] [Related]
9. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord.
Kovács GG; Andó RD; Adori C; Kirilly E; Benedek A; Palkovits M; Bagdy G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):193-203. PubMed ID: 17359360
[TBL] [Abstract][Full Text] [Related]
10. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Wang X; Baumann MH; Xu H; Rothman RB
Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
[TBL] [Abstract][Full Text] [Related]
11. Increased responsiveness to MDMA in adult rats treated neonatally with MDMA.
Piper BJ; Meyer JS
Neurotoxicol Teratol; 2006; 28(1):95-102. PubMed ID: 16271852
[TBL] [Abstract][Full Text] [Related]
12. MDMA-induced serotonergic neurotoxicity enhances aggressiveness in low- but not high-aggressive rats.
Wallinga AE; ten Voorde AM; de Boer SF; Koolhaas JM; Buwalda B
Eur J Pharmacol; 2009 Sep; 618(1-3):22-7. PubMed ID: 19616536
[TBL] [Abstract][Full Text] [Related]
13. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines.
Xie T; Tong L; McLane MW; Hatzidimitriou G; Yuan J; McCann U; Ricaurte G
Neuropsychopharmacology; 2006 Dec; 31(12):2639-51. PubMed ID: 16452989
[TBL] [Abstract][Full Text] [Related]
14. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
15. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days.
Kirilly E; Molnar E; Balogh B; Kantor S; Hansson SR; Palkovits M; Bagdy G
Int J Neuropsychopharmacol; 2008 Sep; 11(6):795-809. PubMed ID: 18261250
[TBL] [Abstract][Full Text] [Related]
16. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
Piper BJ; Vu HL; Safain MG; Oliver AJ; Meyer JS
J Pharmacol Exp Ther; 2006 May; 317(2):838-49. PubMed ID: 16434566
[TBL] [Abstract][Full Text] [Related]
17. A potent non-monoaminergic paradoxical sleep inhibitory system: a reverse microdialysis and single-unit recording study.
Crochet S; Onoe H; Sakai K
Eur J Neurosci; 2006 Sep; 24(5):1404-12. PubMed ID: 16987225
[TBL] [Abstract][Full Text] [Related]
18. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.
Giannaccini G; Betti L; Pirone A; Palego L; Fabiani O; Fabbrini L; Mascia G; Giusti L; Macchia M; Giusiani M; Martini C; Lucacchini A
Neurochem Int; 2007 Dec; 51(8):496-506. PubMed ID: 17602794
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: a possible mechanism of action.
Tatarczyńska E; Antkiewicz-Michaluk L; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
Eur J Pharmacol; 2005 May; 516(1):46-50. PubMed ID: 15913599
[TBL] [Abstract][Full Text] [Related]
20. Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.
Balogh B; Molnar E; Jakus R; Quate L; Olverman HJ; Kelly PA; Kantor S; Bagdy G
Psychopharmacology (Berl); 2004 May; 173(3-4):296-309. PubMed ID: 15083265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
